Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 1 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 5 patents granted in the last 365 days
Hangzhou Zhongmeihuadong Pharmaceutical Co. Ltd. has 2 pending office actions in the Biotechnology & Pharmaceuticals technology area. These are distributed across 2 distinct examiners and 1 distinct art unit. BANERJEE, KOYELI is the busiest examiner, handling 1 busiest examiner pending office action. This means that while the company's current matters are within the same unit, they are being reviewed by different individuals.
The concentration of 2 pending office actions within 1 distinct art unit indicates a focused pharmaceutical scope for the company's current patent activity. However, the involvement of 2 distinct examiners means the company is navigating different individual perspectives within that group. This can lead to variations in how similar pharmaceutical concepts are treated, even when they fall under the same 1 distinct art unit.
With the busiest examiner handling 1 busiest examiner pending office action, the workload is evenly split. Practitioners should be aware that even within 1 distinct art unit, the presence of multiple examiners requires tailored arguments to meet the specific preferences of each person. The 2 pending office actions represent the entirety of the company's current prosecution focus.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BANERJEE, KOYELI | 1 | 50.0% | +0.0% |
| KOROTCHKINA, LIOUBOV G | 1 | 29.5% | +67.7% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18264400 | FERMENTATION METHOD FOR MUPIROCIN | KOROTCHKINA, LIOUBOV G | 12d |
| 18586899 | GIP RECEPTOR AGONIST AND USE THEREOF | BANERJEE, KOYELI | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18264400 | FERMENTATION METHOD FOR MUPIROCIN | KOROTCHKINA, LIOUBOV G | 12d |
| Art Unit | Apps |
|---|---|
| 1653 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18586899 | GIP RECEPTOR AGONIST AND USE THEREOF | BANERJEE, KOYELI | — | §103§112 | Non-Final OA | — | Pending | Feb 26, 2024 |
| 18264400 | FERMENTATION METHOD FOR MUPIROCIN | KOROTCHKINA, LIOUBOV G | 1653 | §103 | Final Rejection | 12d | Pending | Aug 04, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial